Nov 15, 2016
AbbVie (NYSE: ABBV), a global biopharmaceutical company has announced that 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients with severe chronic kidney disease (CKD) achieved sustained virologic response following 12 weeks of treatment (SVR12) with its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in the primary intent-to-treat (ITT) analysis. These new data from the Phase 3 EXPEDITION-4 study that evaluates patients with chronic HCV infection were presented as a late-breaker at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.
Ed Gane, M.D., professor of medicine at the University of Auckland in Auckland, New Zealand, said: “HCV patients with severe chronic kidney disease present a complex challenge for physicians to treat, particularly as kidney disease progresses, and if the patient has genotype 2 or 3 or has compensated cirrhosis. The results seen in EXPEDITION-4 are a positive development in AbbVie’s investigation of the G/P regimen for patients with chronic kidney disease, who currently have limited HCV treatment options.”
“With our investigational, pan-genotypic regimen, our goal is to provide a safe and effective cure to patients across genotypes, including patients with severe chronic kidney disease, regardless of previous treatment status or presence of compensated cirrhosis. Our clinical development program reflects our ongoing commitment to addressing treatment areas of continued unmet need,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie.